Personalized Cancer Vaccines: A New Turning Point for Cancer Treatment?

When quoting or reporting this interview, please explicitly credit the program SBS "News Hunters".
Copyright belongs to SBS.

■ Broadcast: SBS "News Hunters" Mon–Fri ( 18:50–19:50)
■ Anchors: Kim Jong-won, Yoon Tae-jin
■ Guest: Shin Eui-cheol (Professor, KAIST Graduate School of Medical Science and Engineering)
--------------------------------------------

Patient-customized cancer vaccines have recently been drawing significant attention.

The news came as the mRNA cancer treatment jointly developed by U.S. pharmaceutical companies Moderna and Merck achieved its primary endpoints in a Phase 3 clinical trial.

Designed custom-tailored by analyzing the genetic mutations of each individual's cancer cells, the clinical trial for this treatment was initially conducted for melanoma.

We take an in-depth look at when this much-discussed personalized cancer treatment might receive official approval, whether its application can be expanded to other types of cancer, and ultimately, if it can open a new breakthrough in cancer treatment.

※ Detailed information is available in the video clip.
※ Please note: This article was translated by AI and may contain errors.